In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on SAB Biotherapeutics, with a price target of $9.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar’s rating is based on the promising Phase 1 data for SAB Biotherapeutics’ SAB-142, which demonstrates a unique mechanism of action compared to existing treatments. The data presented at the ISPAD 2025 conference highlights SAB-142’s ability to delay the progression of Type 1 Diabetes in Stage 3 patients, showing a tolerable safety profile and differentiation from rabbit ATG and teplizumab.
The treatment’s ability to sustain CD4+ T cell exhaustion without causing prolonged lymphodepletion is a significant advantage, as it avoids the associated risks of a weakened immune system. Additionally, SAB-142 does not induce serum sickness or anti-drug antibodies, which are common with other treatments. These factors contribute to the belief that SAB-142 could achieve similar efficacy in preserving C-peptide levels and improving A1c with fewer safety concerns, supporting the Buy rating.
In another report released on October 21, Leerink Partners also reiterated a Buy rating on the stock with a $0.00 price target.